{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:38:49Z","timestamp":1787002729033,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>From December 2022 to January 2023, the SARS-CoV-2 Omicron BA.5\/BF.7 variant significantly impacted mainland China. While most COVID-19 patients experienced mild symptoms and were treated as outpatients or at home, some cases progressed to severe illness, necessitating hospitalization or even resulting in death. To better understand this outbreak and forecast future waves as SARS-CoV-2 continues to evolve, it is crucial to assess the titer of neutralizing antibodies (Nab) for evaluating the establishment of an immune barrier. In this study, we investigated the dynamic evolution of humoral immunity following the breakthrough infection wave driven by the SARS-CoV-2 Omicron BA.5\/BF.7 variant in southwest China. Over a period of more than one year, we analyzed 3128 serum samples collected monthly to delineate the kinetics of Nab responses in a large cohort. Our data revealed a pronounced surge in Nab titers immediately after the December 2022\u2013January 2023 outbreak, particularly among individuals primed with two or three doses of vaccine. As the epidemic progressed, emerging variants such as XBB.1.5, EG.5, and JN.1 elicited distinct immunological responses and demonstrated varying capacities for immune escape. Our findings underscore the rapid antigenic evolution of SARS-CoV-2 and the consequent challenges in sustaining effective population-level immunity, thereby advocating for continual surveillance and adaptive vaccine immunogen updates.<\/jats:p>","DOI":"10.1038\/s41392-025-02319-3","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T08:29:44Z","timestamp":1753864184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dynamics of neutralizing antibodies against COVID-19 Omicron subvariants following breakthrough infection in southwest China between December 2022 and April 2024"],"prefix":"10.1038","volume":"10","author":[{"given":"Yongquan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiqiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiju","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2319_CR1","doi-asserted-by":"publisher","first-page":"2388938","DOI":"10.1080\/21645515.2024.2388938","volume":"20","author":"M Yang","year":"2024","unstructured":"Yang, M. et al. COVID-19 vaccination and concerns regarding vaccine hesitancy after the termination of the zero-COVID policy in China: a nationwide cross-sectional study. Hum. Vaccines Immunother. 20, 2388938 (2024).","journal-title":"Hum. Vaccines Immunother."},{"key":"2319_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.46234\/ccdcw2022.015","volume":"4","author":"J Liu","year":"2022","unstructured":"Liu, J., Liu, M. & Liang, W. The dynamic COVID-zero strategy in China. China CDC Wkly. 4, 74\u201375 (2022).","journal-title":"China CDC Wkly."},{"key":"2319_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39638-4","volume":"14","author":"EE Goldberg","year":"2023","unstructured":"Goldberg, E. E., Lin, Q., Romero-Severson, E. O. & Ke, R. Swift and extensive Omicron outbreak in China after sudden exit from \u2018zero-COVID' policy. Nat. Commun. 14, 3888 (2023).","journal-title":"Nat. Commun."},{"key":"2319_CR4","doi-asserted-by":"crossref","unstructured":"He, Y. et al. Clinical characteristics of mild patients with breakthrough infection of Omicron variant in China after relaxing the dynamic zero COVID-19 policy. Vaccines. 11, 968 (2023).","DOI":"10.3390\/vaccines11050968"},{"key":"2319_CR5","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1056\/NEJMoa066092","volume":"357","author":"IJ Amanna","year":"2007","unstructured":"Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903\u20131915 (2007).","journal-title":"N. Engl. J. Med."},{"key":"2319_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/s41591-020-1083-1","volume":"26","author":"A Edridge","year":"2020","unstructured":"Edridge, A. et al. Seasonal coronavirus protective immunity is short-lasting. Nat. Med. 26, 1691\u20131693 (2020).","journal-title":"Nat. Med."},{"key":"2319_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrg2323","volume":"9","author":"S Duffy","year":"2008","unstructured":"Duffy, S., Shackelton, L. A. & Holmes, E. C. Rates of evolutionary change in viruses: patterns and determinants. Nat. Rev. Genet. 9, 267\u2013276 (2008).","journal-title":"Nat. Rev. Genet."},{"key":"2319_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009772","volume":"17","author":"M Alenquer","year":"2021","unstructured":"Alenquer, M. et al. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies. Plos Pathog. 17, e1009772 (2021).","journal-title":"Plos Pathog."},{"key":"2319_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41421-023-00569-5","volume":"9","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by breakthrough infection sera from previous and recent waves in China. Cell Discov. 9, 64 (2023).","journal-title":"Cell Discov."},{"key":"2319_CR10","first-page":"100945","volume":"40","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Antibody response assessment of immediate breakthrough infections after zero-COVID policy adjustment in China. Lancet Reg. Health W. Pac. 40, 100945 (2023).","journal-title":"Lancet Reg. Health W. Pac."},{"key":"2319_CR11","doi-asserted-by":"publisher","DOI":"10.4110\/in.2023.23.e43","volume":"23","author":"E Nham","year":"2023","unstructured":"Nham, E. et al. Low neutralizing activities to the Omicron subvariants BN.1 and XBB.1.5 of Sera from the individuals vaccinated with a BA.4\/5-containing bivalent mRNA vaccine. Immune Netw. 23, e43 (2023).","journal-title":"Immune Netw."},{"key":"2319_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/318323a0","volume":"318","author":"RM Anderson","year":"1985","unstructured":"Anderson, R. M. & May, R. M. Vaccination and herd immunity to infectious diseases. Nature 318, 323\u2013329 (1985).","journal-title":"Nature"},{"key":"2319_CR13","unstructured":"China CDC, Novel Coronavirus Infection. https:\/\/www.chinacdc.cn\/jkzt\/crb\/zl\/szkb_11803\/ (2024)."},{"key":"2319_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00813-7","volume":"24","author":"Y Kaku","year":"2024","unstructured":"Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. Lancet Infect. Dis. 24, e82 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"2319_CR15","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1016\/S1473-3099(23)00744-2","volume":"24","author":"S Yang","year":"2024","unstructured":"Yang, S. et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect. Dis. 24, e70\u2013e72 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"2319_CR16","doi-asserted-by":"publisher","first-page":"107028","DOI":"10.1016\/j.ijid.2024.107028","volume":"143","author":"J Favresse","year":"2024","unstructured":"Favresse, J. et al. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster. Int. J. Infect. Dis. 143, 107028 (2024).","journal-title":"Int. J. Infect. Dis."},{"key":"2319_CR17","doi-asserted-by":"crossref","unstructured":"Abul, Y. et al. Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents. GeroScience, 47, 1887\u20131896 (2025).","DOI":"10.1007\/s11357-024-01346-2"},{"key":"2319_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06162-6","volume":"23","author":"D Li","year":"2025","unstructured":"Li, D. et al. Function and structure of broadly neutralizing antibodies against SARS-CoV-2 Omicron variants isolated from prototype strain infected convalescents. J. Transl. Med. 23, 212 (2025).","journal-title":"J. Transl. Med."},{"key":"2319_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01223-24","volume":"98","author":"SC Stein","year":"2024","unstructured":"Stein, S. C. et al. A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation. J. Virol. 98, e122324 (2024).","journal-title":"J. Virol."},{"key":"2319_CR20","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S0140-6736(20)30567-5","volume":"395","author":"RM Anderson","year":"2020","unstructured":"Anderson, R. M., Heesterbeek, H., Klinkenberg, D. & Hollingsworth, T. D. How will country-based mitigation measures influence the course of the COVID-19 epidemic?. Lancet 395, 931\u2013934 (2020).","journal-title":"Lancet"},{"key":"2319_CR21","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1126\/science.abb5793","volume":"368","author":"SM Kissler","year":"2020","unstructured":"Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H. & Lipsitch, M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 368, 860\u2013868 (2020).","journal-title":"Science"},{"key":"2319_CR22","doi-asserted-by":"publisher","first-page":"e1008409","DOI":"10.1371\/journal.pcbi.1008409","volume":"16","author":"KM Gostic","year":"2020","unstructured":"Gostic, K. M. et al. Practical considerations for measuring the effective reproductive number, Rt. Plos Comput. Biol. 16, e1008409 (2020).","journal-title":"Plos Comput. Biol."},{"key":"2319_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30711-y","volume":"13","author":"M Ghafari","year":"2022","unstructured":"Ghafari, M., Watson, O. J., Karlinsky, A., Ferretti, L. & Katzourakis, A. A framework for reconstructing SARS-CoV-2 transmission dynamics using excess mortality data. Nat. Commun. 13, 3015 (2022).","journal-title":"Nat. Commun."},{"key":"2319_CR24","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1016\/j.cell.2021.03.027","volume":"184","author":"SA Clark","year":"2021","unstructured":"Clark, S. A. et al. SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. Cell 184, 2605\u20132617 (2021).","journal-title":"Cell"},{"key":"2319_CR25","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1001\/jama.2021.11656","volume":"326","author":"TA Bates","year":"2021","unstructured":"Bates, T. A. et al. Age-dependent neutralization of SARS-CoV-2 and P.1 variant by vaccine immune serum samples. JAMA 326, 868\u2013869 (2021).","journal-title":"JAMA"},{"key":"2319_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2249121","volume":"12","author":"H Wang","year":"2023","unstructured":"Wang, H. et al. Neutralization against Omicron subvariants after BA.5\/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination(1). Emerg. Microbes Infect. 12, 2249121 (2023).","journal-title":"Emerg. Microbes Infect."},{"key":"2319_CR27","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/jalm\/jfae014","volume":"9","author":"B Lee","year":"2024","unstructured":"Lee, B. et al. Age-related differences in neutralizing antibody responses against SARS-CoV-2 Delta and Omicron variants in 151 SARS-CoV-2-Naive metropolitan residents boosted with BNT162b2. J. Appl. Lab. Med. 9, 741\u2013751 (2024).","journal-title":"J. Appl. Lab. Med."},{"key":"2319_CR28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.immuni.2020.08.003","volume":"53","author":"MJ Bunders","year":"2020","unstructured":"Bunders, M. J. & Altfeld, M. Implications of sex differences in immunity for SARS-CoV-2 pathogenesis and design of therapeutic interventions. Immunity 53, 487\u2013495 (2020).","journal-title":"Immunity"},{"key":"2319_CR29","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/infdis\/jiab127","volume":"224","author":"L Grzelak","year":"2021","unstructured":"Grzelak, L. et al. Sex differences in the evolution of neutralizing antibodies to severe acute respiratory syndrome Coronavirus 2. J. Infect. Dis. 224, 983\u2013988 (2021).","journal-title":"J. Infect. Dis."},{"key":"2319_CR30","doi-asserted-by":"publisher","first-page":"2300208","DOI":"10.1080\/21645515.2023.2300208","volume":"20","author":"R Yuan","year":"2024","unstructured":"Yuan, R. et al. Enhanced immunity against SARS-CoV-2 in returning Chinese individuals. Hum. Vaccines Immunother. 20, 2300208 (2024).","journal-title":"Hum. Vaccines Immunother."},{"key":"2319_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-21317-x","volume":"12","author":"HT Zedan","year":"2022","unstructured":"Zedan, H. T. et al. Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies. Sci. Rep. 12, 19020 (2022).","journal-title":"Sci. Rep."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02319-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02319-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02319-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T07:35:48Z","timestamp":1757316948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02319-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2319"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02319-3","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"4 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"242"}}